CA-VELODYNE-LIDAR,-INC.
7.1.2020 21:02:10 CET | Business Wire | Press release
Velodyne Lidar, Inc. today introduced Velabit™, Velodyne’s smallest sensor which brings new levels of versatility and affordability to 3D lidar perception, at CES 2020. The Velabit leverages Velodyne’s innovative lidar technology and manufacturing partnerships for cost optimization and high-volume production. The sensor advances Velodyne’s mission to make high-quality 3D lidar sensors readily accessible to everyone.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005849/en/
The Velabit perfectly complements Velodyne’s sensor portfolio. The sensor delivers the same technology and performance found on Velodyne’s full suite of state-of-the-art sensors and will be the catalyst for creating endless possibilities for new applications in a variety of industries. The compact Velabit can be embedded almost anywhere within vehicles, robots, unmanned aerial vehicles (UAVs), infrastructure and more. It is designed to be easy to manufacture at mass production levels.
The Velabit is engineered to be an optimal automotive grade lidar solution for Advanced Driver Assistance Systems (ADAS) and autonomous vehicles. It enables robust perception coverage for Blind-Spot Monitoring, Cross Traffic Detection, Automatic Emergency Braking, and Pedestrian and Bicyclist Safety. Highly configurable for customer application, this mid-range sensor can be combined with other Velodyne lidar sensors, such as the Velarray™, for high-speed operation or function as a standalone lidar solution in low-speed applications.
The Velabit addresses the cost, safety and design challenges of autonomous solutions while delivering strong sensor performance. Here are the Velabit’s leading features:
- Integrated processing in a compact size of 2.4” x 2.4” x 1.38” – smaller than a deck of playing cards – to be easily embedded in a wide range of solutions.
- Range up to 100 meters.
- Outstanding field of view (FoV): 60-degree horizontal FoV x 10-degree vertical FoV.
- Highly configurable to support a range of applications.
- Proven, Class 1 eye-safe 903 nanometer technology.
- Bottom connector with cable length options.
- Multiple manufacturing sources scheduled to be available for qualified production projects.
“The Velabit democratizes lidar with its ultra-small form factor and its sensor pricing targeted at $100 in high-volume production, making 3D lidar available for all safety-critical applications,” said Anand Gopalan, Chief Executive Officer, Velodyne Lidar. “Its combination of performance, size and price position the Velabit to drive a quantum leap in the number of lidar-powered applications. The sensor delivers what the industry has been seeking: a breakthrough innovation that can jump-start a new era of autonomous solutions on a global scale.”
“Before the Velabit there was no suitable small and lightweight lidar for small unmanned aerial vehicles and unmanned ground vehicles performing obstacle avoidance or mapping,” said Alberto Lacaze, president, Robotic Research. “Since Robotic Research’s Pegasus Mini™ is a fully autonomous ground and air vehicle, it requires the Velabit’s size and versatility. In addition, the Velabit enables the most advanced GPS-denied HD mapping in the industry. The Velabit fills a much-needed space in the market and is currently in a class of its own.”
The Velabit will be available to customers mid-2020. Velodyne provides world-class technical support for the sensor across North America, Europe and Asia. It is now on display at Velodyne Lidar’s CES 2020 booth located at the Las Vegas Convention Center North Hall – booth #7520.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s Founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™ and the groundbreaking software for driver assistance, Vella™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005849/en/
Contact:
Sean Dowdall Landis Communications Inc. for Velodyne Lidar, Inc. (415) 286-7121 velodyne@landispr.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom